Tag: Novartis

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market cap and sales.

Novartis and AbCellera in Multi-Target, Multi-Year Collaboration

AbCellera, a technology leader in therapeutic antibody discovery from natural immune repertoires, announced a multi-target and multi-year collaboration with Novartis. Under the agreement, AbCellera wi...

Novartis Tropical Disease Drug Got FDA Approval

Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This makes Egaten the...

Clinigen Acquire Novartis’ Rights for Drug

Clinigen Group plc, the global pharmaceutical and services company, has signed an agreement with Novartis to acquire the US rights to Proleukin® (aldesleukin, human recombinant interleukin-2) for up t...

NICE Approved Novartis’ DLBCL Drug for Non-Responding Patients

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments. The drug will be fun...

$15b on M&A from Novartis in 2018, Tendency to Grow

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis’ four...

Novartis Statement Regarding No-Deal Brexit

Novartis has issued a statement expressing concern over the state of medicine supply to the UK, and noting that it is building increased inventories across its portfolio of medicines in the UK. The...

Novartis and Oxford University Join Forces for 5-Year Research

Novartis and Oxford University have begun a partnership that will attempt to use artificial intelligence to predict how patients will respond to new and existing treatments for inflammatory diseases s...

Big Pharma’s Experts Go to Biotech

Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZeneca. Vo...

Companies with Most FDA Approvals

In 2018, the U.S. Food and Drug Administration (FDA) approved 59 novel drugs, meaning approved new molecular entities (NMEs). The figure for 2017 was 46 novel drugs. The FDA notes, “Each year, CDER a...

Generic for Alzheimer’s and Parkinson’s Approved by FDA

The U.S. Food and Drug Administration (FDA) approved Bridgewater, NJ-based Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to A...

Novartis Wins Breakthrough Designation

A monthly antibody drug to treat sickle cell disease, developed by Novartis, has won a coveted breakthrough designation from the FDA as it heads towards its first regulatory filings. The US regulat...

NHS to Fund its TSC-Related Refractory Epilepsy Drug

NHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy from April 2019. The drug has a patchy history with the health s...

Novartis to Strengthen Cell and Gene Manufacturing Capabilities

Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering to acquire CDMO CellforCure, manufacturers o...

First FDA-Cleared PDT for Opioid Use Disorder

Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted clearanc...

Novartis to Test Pear’s Digital Therapeutic Treatment for Schizophrenia

Over the past year, Pear has shown it can convince regulators of the safety and efficacy of digital therapeutics by winning approvals for its treatments for substance use disorder, and most recently, ...

Big Pharma Companies to Raise Drug Prices in January

Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry...